Jennifer A Woyach, MD
Leadership Title: Co-Leader, Leukemia and Hematologic Malignancies Program
Academic Title: Professor in the College of Medicine
Research Program: Leukemia and Hematologic Malignancies
About Me
More info forI am a hematologist-oncologist who specializes in treating patients with blood cancers, particularly chronic lymphocytic leukemia (CLL) and B-cell lymphomas. I also serve as a professor in the Division of Hematology at The Ohio State University. Our approach to patient care is truly unique at the OSUCCC – James. We work in teams of specialists, subspecialists and super subspecialists to better treat specific cancers while never forgetting the power and value of personalized, patient-centered care. I was named to the Castle Connolly list of “Regional Top Doctors” in 2019, as well as being rated in the top 10 percent of physicians in the nation for patient satisfaction in 2017. As co-leader of the Leukemia and Hematologic Malignancies Program at the OSUCCC – James, my research focuses on targeted therapies for CLL and strategies to overcome resistance to targeted therapies. I led the collaborative effort that identified the mechanism of resistance to the BTK inhibitor ibrutinib in CLL and have led preclinical and clinical studies to identify drugs that can overcome ibrutinib resistance. Most recently, I led a multi-institutional phase III clinical trial that showed older patients with CLL have a significantly lower rate of disease progression if treated with ibrutinib rather than with bendamustine plus rituximab — a regimen previously considered as one of the most effective therapies for this group of patients. It was the first head-to-head comparison between the two treatments. Results were reported simultaneously in the New England Journal of Medicine (NEJM) and in the plenary session at the American Society of Hematology (ASH) 2018 Annual Meeting. In 2015, I was honored with a Young Physician-Scientist Award from the American Society of Clinical Investigation. My work has been featured in several medical publications, including Journal of Clinical Oncology, Lancet Oncology, Blood and Cancer Discovery. I have also shared my research at multiple conferences, including ASH, the American Society of Clinical Oncology (ASCO) Annual Meeting and the International Workshop on Chronic Lymphocytic Leukemia (iwCLL). At The James, we know that there are no routine cancers. That's why I stay current with new knowledge in my field as a participant in several professional associations. I'm a member of the American Society of Clinical Oncology, the American Association for Cancer Research and the American Society of Hematology, where I serve on a number of subcommittes. I also serve as a member of the Leukemia Committee and the Cancer in the Elderly Committee for the Alliance for Clinical Trials in Oncology, which is a group of cancer centers that designs and runs clinical trials to help improve the care of CLL patients around the country. By working with other specialists around the country, we can improve our understanding of CLL biology and therapy, and I can apply this knowledge to improve the lives of the patients we see here at the James.
Clinical Expertise
More info for- Hematology
- Hairy Cell Leukemia
- Chronic Lymphocytic Leukemias
- Leukemia, Myeloid
- Blood Cancers
Research Interests
More info for- Thyroid Neoplasms
- Neoplasms, Second Primary
- Listeriosis
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia
- Agammaglobulinemia
- Lymphocytosis
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Chromosome Aberrations
- Tumor Lysis Syndrome
Where I See Patients
More info forEducation & Training
More info forMedical School
- Ohio State University College of Medicine
370 W 9Th Ave, Columbus, OH
Fellowship - Hematology & Oncology
- Ohio State University Wexner Medical Center
700 Ackerman Rd, Columbus, OH
Internship - Internal Medicine
- Ohio State University Wexner Medical Center
700 Ackerman Rd, Columbus, OH
Residency - Internal Medicine
- Ohio State University Wexner Medical Center
700 Ackerman Rd, Columbus, OH
- Ohio State University College of Medicine
Academic Office & Contact Information
More info forAcademic Office:
Comprehensive Cancer Center 0455D
410 W 12th Ave
Columbus, Ohio 43210-1214Phone:
614-685-5667Email:
woyach.2@osu.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Videos
More info forPublications
More info forOctober 3, 2024Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.
Shah NN, Wang M, Roeker LE, Patel K, Woyach JA, Wierda WG, Ujjani CS, Eyre TA, Zinzani PL, Alencar AJ, Ghia P, Lamanna N, Hoffmann MS, Patel MR, Flinn I, Gerson JN, Ma S, Coombs CC, Cheah CY, Lech-Maranda E, Fakhri B, Kim WS, Barve MA, Cohen JB, Jurczak W, Munir T, Thompson MC, Tsai DE, Bao K, Cangemi NA, Kherani JF, Walgren RA, Han H, Ruppert AS, Brown JR
Haematologica
October 1, 2024Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy.
Lamanna N, Tam CS, Woyach JA, Alencar AJ, Palomba ML, Zinzani PL, Flinn IW, Fakhri B, Cohen JB, Kontos A, Konig H, Ruppert AS, Chatterjee A, Sizelove R, Compte L, Tsai DE, Jurczak W
EJHaem
September 1, 2024Pericardial events associated with ibrutinib-based therapies for chronic lymphocytic leukaemia in two landmark trials.
Fakhri B, Wang V, Perez-Burbano G, Wall A, Mandrekar S, Parikh SA, Woyach J, Shanafelt T
Br J Haematol
August 17, 2024Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiation.
Gambril JA, Ghazi SM, Sansoterra S, Ferdousi M, Kola-Kehinde O, Ruz P, Kittai AS, Rogers K, Grever M, Bhat S, Wiczer T, Byrd JC, Woyach J, Addison D
Leukemia
August 8, 2024LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclax-resistant chronic lymphocytic leukemia.
Ravikrishnan J, Diaz-Rohena DY, Muhowski E, Mo X, Lai TH, Misra S, Williams CD, Sanchez J, Mitchell A, Satpati S, Perry E, Kaufman T, Liu C, Lozanski A, Lozanski G, Rogers K, Kittai AS, Bhat SA, Collins MC, Davids MS, Jain N, Wierda WG, Lapalombella R, Byrd JC, Tan F, Chen Y, Chen Y, Shen Y, Anthony SP, Woyach JA, Sampath D
Haematologica
July 18, 2024Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study.
Wierda WG, Shah NN, Cheah CY, Lewis D, Hoffmann MS, Coombs CC, Lamanna N, Ma S, Jagadeesh D, Munir T, Wang Y, Eyre TA, Rhodes JM, McKinney M, Lech-Maranda E, Tam CS, Jurczak W, Izutsu K, Alencar AJ, Patel MR, Seymour JF, Woyach JA, Thompson PA, Abada PB, Ho C, McNeely SC, Marella N, Nguyen B, Wang C, Ruppert AS, Nair B, Liu H, Tsai DE, Roeker LE, Ghia P
Lancet Haematol
June 11, 2024Fixed-Duration Pirtobrutinib plus Venetoclax with or without Rituximab in Relapsed/Refractory CLL: Phase 1b BRUIN Trial.
Roeker LE, Woyach JA, Cheah CYY, Coombs CC, Shah NN, Wierda WG, Patel MR, Lamanna N, Tsai DE, Nair BC, Wang C, Zhao X, Liu D, Radtke D, Chapman S, Marella N, McNeely SC, Brown JR
Blood
May 31, 2024Covalent Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Alsouqi A, Woyach JA
Clin Lymphoma Myeloma Leuk
May 16, 2024Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib.
Woyach JA, Jones D, Jurczak W, Robak T, Illes A, Kater AP, Ghia P, Byrd JC, Seymour JF, Long S, Mohamed N, Benrashid S, Lai TH, De Jesus G, Lai R, de Bruin G, Rule S, Munugalavadla V
Blood
April 28, 2024Determining the relationship of p16INK4a and additional molecular markers of aging with clinical frailty in hematologic malignancy.
Rosko AE, Elsaid MI, Woyach J, Islam N, Lepola N, Urrutia J, Christian LM, Presley C, Mims A, Burd CE
J Cancer Surviv
April 19, 2024Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: Pooled analysis of 5 clinical trials.
Davids MS, Sharman JP, Ghia P, Woyach JA, Eyre TA, Jurczak W, Siddiqi T, Palhares de Miranda PA, Shahkarami M, Butturini AM, Emeribe U, Byrd JC
Blood Adv
April 17, 2024Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia.
Patton JT, Woyach JA
Semin Hematol
April 1, 2024Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024.
Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Cortese M, Cripe L, Davis RS, Eradat H, Fakhri B, Fletcher CD, Gaballa S, Hamid MS, Hill B, Kaesberg P, Kahl B, Kamdar M, Kipps TJ, Ma S, Mosse C, Nakhoda S, Parikh S, Schorr A, Schuster S, Seshadri M, Siddiqi T, Stephens DM, Thompson M, Ujjani C, Valdez R, Wagner-Johnston N, Woyach JA, Sundar H, Dwyer M
J Natl Compr Canc Netw
March 29, 2024Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.
Kittai AS, Bond D, Huang Y, Bhat SA, Blyth E, Byrd JC, Chavez JC, Davids MS, Dela Cruz JP, Dowling MR, Duffy C, Ho C, Jacobson C, Jaglowski S, Jain N, Lin KH, Miller C, McCarthy C, Omer Z, Parry E, Rai M, Rogers KA, Saha A, Schachter L, Scott H, Senapati J, Shadman M, Siddiqi T, Stephens DM, Vanguru V, Wierda W, Woyach JA, Thompson PA
J Clin Oncol
March 27, 2024A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
Hampel PJ, Swaminathan M, Rogers KA, Parry EM, Burger JA, Davids MS, Ding W, Ferrajoli A, Hyak JM, Jain N, Kenderian SS, Wang Y, Wierda WG, Woyach JA, Parikh SA, Thompson PA
Blood Adv
March 4, 2024The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling.
Marr AR, Halpin M, Corbin DL, Asemelash Y, Sher S, Gordon BK, Whipp EC, Mitchell S, Harrington BK, Orwick S, Benrashid S, Goettl VM, Yildiz V, Mitchell AD, Cahn O, Mims AS, Larkin KTM, Long M, Blachly J, Woyach JA, Lapalombella R, Grieselhuber NR
Exp Hematol Oncol
February 19, 2024Comparison of karyotype scoring guidelines for evaluating karyotype complexity in chronic lymphocytic leukemia.
Avenarius MR, Huang Y, Kittai AS, Bhat SA, Rogers KA, Grever MR, Woyach JA, Miller CR
Leukemia
February 15, 2024Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma accounting for small molecule inhibitors: A real-world cohort analysis.
Kittai AS, Hang Y, Bhat SA, Clark A, Grever M, Rhodes JM, Roberts M, Rogers KA, Teschemaker A, Munoz-Sagastibelza M, Woyach JA, Barrientos JC
Am J Hematol
January 12, 2024Long-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL.
Woyach JA, Perez Burbano GE, Ruppert AS, Miller CR, Heerema NA, Zhao W, Wall A, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Stephens DM, Brown JR, Lozanski G, Blachly JS, Nattam S, Larson RA, Erba HP, Litzow MR, Luger SM, Owen C, Kuzma C, Abramson JS, Little RF, Dinner SN, Stone RM, Uy GL, Stock W, Mandrekar SJ, Byrd JC
Blood
January 9, 2024A Bayesian framework to study tumor subclone-specific expression by combining bulk DNA and single-cell RNA sequencing data.
Qiao Y, Huang X, Moos PJ, Ahmann JM, Pomicter AD, Deininger MW, Byrd JC, Woyach JA, Stephens DM, Marth GT
Genome Res
January 1, 2024NOD2 activation enhances macrophage Fcγ receptor function and may increase the efficacy of antibody therapy.
Merchand-Reyes G, Bull MF, Santhanam R, Valencia-Pena ML, Murugesan RA, Chordia A, Mo XM, Robledo-Avila FH, Ruiz-Rosado JD, Carson WE, Byrd JC, Woyach JA, Tridandapani S, Butchar JP
Front Immunol
December 18, 2023Active Hexose-Correlated Compound Shows Direct and Indirect Effects against Chronic Lymphocytic Leukemia.
Merchand-Reyes G, Santhanam R, Valencia-Pena ML, Kumar K, Mo X, Belay T, Woyach JA, Mundy-Bosse B, Tridandapani S, Butchar JP
Nutrients
December 1, 2023Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical Studies.
Gopalakrishnan S, Menon R, Suleiman AA, Kater AP, Stilgenbauer S, Seymour JF, Chyla B, Lu T, Young Kim S, Roberts AW, Woyach JA, Mensing S, Salem AH
Hemasphere
November 6, 2023First in Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma.
Woyach JA, Stephens DM, Flinn IW, Bhat SA, Savage RE, Chai F, Eathiraj S, Reiff SD, Muhowski EM, Granlund L, Szuszkiewicz L, Wang W, Schwartz B, Ghori R, Farooqui MZH, Byrd JC
Cancer Discov
October 18, 2023Characteristics and Outcomes of Patients with CLL and CDKN2A/B Deletion by Fluorescence in situ Hybridization.
Teierle SM, Huang Y, Kittai AS, Bhat SA, Grever MR, Rogers KA, Zhao W, Jones D, Byrd JC, Avenarius MR, Heerema NA, Woyach JA, Miller CR
Blood Adv
October 1, 2023Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review.
Quartermaine C, Ghazi SM, Yasin A, Awan FT, Fradley M, Wiczer T, Kalathoor S, Ferdousi M, Krishan S, Habib A, Shaaban A, Kola-Kehinde O, Kittai AS, Rogers KA, Grever M, Ruz P, Bhat S, Dickerson T, Byrd JC, Woyach J, Addison D
JACC CardioOncol
July 1, 2023Correction: Evaluation of bleeding events in patients receiving acalabrutinib therapy.
Kumar PS, Wiczer T, Rosen L, Pollauf AJ, Zheng A, Palettas M, Azali L, Bhat SA, Byrd JC, Grever MR, Rogers KA, Woyach JA, Kittai AS
Leukemia
May 11, 2023Time-Limited Initial Therapy for Young, Fit Patients with CLL.
Woyach JA, Byrd JC
N Engl J Med
April 3, 2023Refining prognosis in chronic lymphocytic leukemia with normal Fluorescence in situ hybridization results.
Avenarius MR, Huang Y, Hyak J, Byrd JC, Bhat SA, Grever M, Kittai AS, Rogers KA, Jones D, Zhao W, Heerema NA, Abruzzo LV, Woyach J, Miller CR
Hematol Oncol
March 17, 2023Evaluation of bleeding events in patients receiving acalabrutinib therapy.
Kumar PS, Wiczer T, Rosen L, Pollauf AJ, Zheng A, Palettas M, Azali L, Bhat SA, Byrd JC, Grever MR, Rogers KA, Woyach JA, Kittai AS
Leukemia
February 2, 2023Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated Cardiotoxicity.
Buck B, Chum AP, Patel M, Carter R, Nawaz H, Yildiz V, Ruz P, Wiczer T, Rogers KA, Awan FT, Bhat S, Guha A, Kittai AS, Simonetti OP, Raman SV, Wallace G, Sanchez R, Bonsu JM, Gambril J, Haddad D, Mann J, Wei L, Kola-Kehinde O, Byrd JC, Woyach JA, Addison D
JAMA Oncol
January 6, 2023Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter's transformation.
Hing ZA, Walker JS, Whipp EC, Brinton L, Cannon M, Zhang P, Sher S, Cempre CB, Brown F, Smith PL, Agostinelli C, Pileri SA, Skinner JN, Williams K, Phillips H, Shaffer J, Beaver LP, Pan A, Shin K, Gregory CT, Ozer GH, Yilmaz SA, Harrington BK, Lehman AM, Yu L, Coppola V, Yan P, Scherle P, Wang M, Pitis P, Xu C, Vaddi K, Chen-Kiang S, Woyach J, Blachly JS, Alinari L, Yang Y, Byrd JC, Baiocchi RA, Blaser BW, Lapalombella R
Nat Commun
November 15, 2022Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia.
Muhowski EM, Ravikrishnan J, Gordon B, Yu L, Misra S, Walker B, Eathiraj S, Sampath D, Rogers KA, Byrd JC, Woyach JA
J Hematol Oncol
November 14, 2022VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia.
Sher S, Whipp E, Walker J, Zhang P, Beaver L, Williams K, Orwick S, Ravikrishnan J, Walker B, Perry E, Gregory C, Purcell M, Pan A, Yan P, Alinari L, Johnson AJ, Frigault MM, Greer JM, Hamdy A, Izumi R, Mo X, Sampath D, Woyach J, Blachly J, Byrd JC, Lapalombella R
Leukemia
November 1, 2022Management of relapsed/refractory Chronic Lymphocytic Leukemia.
Woyach JA
Am J Hematol
October 26, 2022HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemia.
Lai TH, Ozer HG, Gasparini P, Nigita G, Distefano R, Yu L, Ravikrishnan J, Yilmaz S, Gallegos JJ, Shukla SA, Puduvalli VK, Woyach JA, Lapalombella R, Blachly JS, Byrd JC, Sampath D
Blood Adv
October 10, 2022Patient characteristics that predict Richter's Transformation in patients with CLL treated with ibrutinib.
Kittai AS, Huang Y, Beckwith KA, Bhat SA, Bond DA, Byrd JC, Goldstein D, Grever MR, Miller C, Rogers KA, Yano M, Woyach JA
Am J Hematol
October 1, 2022CLL-116 BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed-Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress).
Wierda WG, Pagel JM, Davids MS, Zinzani PL, Lu Y, Liu H, Shahda S, Leow CC, Tam CS, Woyach J, Eyre TA, Mato AR
Clin Lymphoma Myeloma Leuk
October 1, 2022CLL-120 Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study.
Coombs CC, Pagel JM, Shah NN, Lamanna N, Munir T, Lech-Maranda E, Eyre TA, Woyach JA, Wierda WG, Cheah CY, Cohen JB, Roeker LE, Patel MR, Fakhri B, Barve MA, Tam CS, Lewis D, Gerson JN, Alencar A, Ujjani C, Flinn I, Sundaram S, Ma S, Jagadeesh D, Rhodes J, Taylor J, Abdel-Wahab O, Ghia P, Schuster SJ, Wang D, Nair B, Zhu E, Tsai DE, Davids MS, Brown JR, Jurczak W, Mato AR
Clin Lymphoma Myeloma Leuk
October 1, 2022CLL-418 Characteristics and Clinical Outcomes of Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Long-Term Ibrutinib Treatment in the RESONATE-2 Study.
Woyach JA, Barr PM, Kipps TJ, Barrientos JC, Ahn IE, Ghia P, Girardi V, Hsu E, Jermain M, Burger JA
Clin Lymphoma Myeloma Leuk
August 22, 2022Disruption of Nurse-like Cell Differentiation as a Therapeutic Strategy for Chronic Lymphocytic Leukemia.
Merchand-Reyes G, Santhanam R, Robledo-Avila FH, Weigel C, Ruiz-Rosado JD, Mo X, Partida-Sánchez S, Woyach JA, Oakes CC, Tridandapani S, Butchar JP
Journal of Immunology
August 2, 2022Ventricular Arrhythmias and Sudden Death Events following Acalabrutinib initiation.
Bhat SA, Gambril JA, Azali L, Chen ST, Rosen L, Palettas M, Wiczer T, Kalathoor S, Zhao Q, Rogers KA, Kittai AS, Grever MR, Awan FT, Ruz P, Byrd JC, Woyach JA, Addison D
Blood
July 19, 2022Leukemia-initiating HSCs in chronic lymphocytic leukemia reveal clonal leukemogenesis and differential drug sensitivity.
Chiang CL, Hu EY, Chang L, Labanowska J, Zapolnik K, Mo X, Shi J, Doong TJ, Lozanski A, Yan PS, Bundschuh R, Walker LA, Gallego-Perez D, Lu W, Long M, Kim S, Heerema NA, Lozanski G, Woyach JA, Byrd JC, Lee LJ, Muthusamy N
Cell Rep
July 14, 2022Combined BCL2 and BTK Inhibition in CLL Demonstrates Efficacy after Monotherapy with Both Classes.
Hyak JM, Huang Y, Rogers KA, Bhat SA, Grever MR, Byrd JC, Kittai AS, Jones D, Miller CR, Woyach JA
Blood Adv
July 14, 2022Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation.
Chen ST, Azali L, Rosen L, Zhao Q, Wiczer T, Palettas M, Gambril J, Kola-Kehinde O, Ruz P, Kalathoor S, Rogers K, Kittai A, Grever M, Awan F, Byrd JC, Woyach J, Bhat SA, Addison D
J Hematol Oncol
June 27, 2022Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL.
Yano M, Nunes J, Mo XM, Rogers KA, Woyach JA, Byrd JC, Muthusamy N
Blood Adv
June 1, 2022NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Chanan-Khan AA, Coutre SE, Davis RS, Eradat H, Fletcher CD, Gaballa S, Ghobadi A, Hamid MS, Hernandez-Ilizaliturri F, Hill B, Kaesberg P, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Mato A, Mosse C, Schuster S, Siddiqi T, Stephens DM, Ujjani C, Wagner-Johnston N, Woyach JA, Ye JC, Dwyer MA, Sundar H
J Natl Compr Canc Netw
May 24, 2022Selinexor combined with ibrutinib demonstrates tolerability and safety in advanced B-cell malignancies: A phase I study.
Stephens DM, Huang Y, Ruppert AS, Walker JS, Canfield D, Cempre CB, Fu Q, Baker S, Hu B, Shah H, Vadeboncoeur R, Rogers KA, Bhat S, Jaglowski SM, Lockman H, Lapalombella R, Byrd JC, Woyach JA
Clin Cancer Res
April 29, 2022Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapy.
Yano M, Sharpe C, Lance JR, Ravikrishnan J, Zapolnik K, Mo XM, Woyach JA, Sampath D, Kittai AS, Vasu S, Bhat SA, Rogers KA, Lee D, Muthusamy N, Byrd JC
Blood Adv
April 27, 2022Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib and acalabrutinib treated patients.
Black GS, Huang X, Qiao Y, Tarapcsak S, Rogers KA, Misra S, Byrd JC, Marth GT, Stephens DM, Woyach JA
Blood
January 1, 2022Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Ferrant E, Wierda WG, Munugalavadla V, Yu T, Wang MH, Byrd JC
Leukemia
November 21, 2021Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients.
Zeng C, Evans JP, Reisinger S, Woyach J, Liscynesky C, Boghdadly ZE, Rubinstein MP, Chakravarthy K, Saif L, Oltz EM, Gumina RJ, Shields PG, Li Z, Liu SL
Cell Biosci
November 17, 2021Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past is Prologue" (Shakespeare).
Mato AR, Davids MS, Sharman J, Roeker LE, Kay N, Kater A, Rogers K, Thompson MC, Rhodes J, Goy A, Skarbnik A, Schuster SJ, Tam CS, Eyre TA, O'Brien S, Nabhan C, Lamanna N, Sun C, Shadman M, Pagel JM, Ujjani C, Brander D, Coombs CC, Jain N, Cheah CY, Brown JR, Seymour JF, Woyach JA
Clin Cancer Res
November 3, 2021Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia.
Walker JS, Hing ZA, Sher S, Cronin J, Williams K, Harrington B, Skinner JN, Cempre CB, Gregory CT, Pan A, Yano M, Beaver LP, Walker BR, Labanowska JM, Heerema NA, Mrózek K, Woyach JA, Ruppert AS, Lehman A, Ozer HG, Coppola V, Yan P, Byrd JC, Blachly JS, Lapalombella R
Nat Commun
October 4, 2021Illness representations and psychological outcomes in chronic lymphocytic leukaemia.
Arrato NA, Valentine TR, Byrd JC, Jones JA, Maddocks KJ, Woyach JA, Andersen BL
Br J Health Psychol
August 20, 2021Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.
Staber PB, Jurczak W, Greil R, Vucinic V, Middeke JM, Montillo M, Munir T, Neumeister P, Schetelig J, Stilgenbauer S, Striebel F, Dirnberger-Hertweck M, Weirather J, Brugger W, Kelemen P, Wendtner CM, Woyach JA
Leuk Lymphoma
August 13, 2021Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Woyach J, Tedeschi A, Munir T, Siddiqi T, Hillmen P, Byrd JC, Ghia P, Mulligan SP, Dai S, Amaya-Chanaga CI, Dean JP, O'Brien SM, Barr PM
Leuk Lymphoma
August 9, 2021Optimizing extracellular vesicles' isolation from chronic lymphocytic leukemia patient plasma and cell line supernatant.
Elgamal S, Cocucci E, Sass EJ, Mo XM, Blissett AR, Calomeni EP, Rogers KA, Woyach JA, Bhat SA, Muthusamy N, Johnson AJ, Larkin KT, Byrd JC
JCI Insight
August 1, 2021Genomics of Resistance to Targeted Therapies.
Thangavadivel S, Woyach JA
Hematol Oncol Clin North Am
July 27, 2021The impact of increasing karyotypic complexity and evolution on survival in CLL patients treated with ibrutinib.
Kittai AS, Miller CR, Goldstein D, Huang Y, Abruzzo LV, Beckwith KA, Bhat S, Bond DA, Grever MR, Heerema NA, Rogers KA, Ruppert AS, Byrd JC, Woyach JA
Blood
July 17, 2021Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.
Ruppert AS, Booth AM, Ding W, Bartlett NL, Brander DM, Coutre S, Brown JR, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma CS, Abramson JS, Little RF, Smith SE, Stone RM, Byrd JC, Mandrekar SJ, Woyach JA
Leukemia
July 3, 2021A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia.
Cheung MC, Mittmann N, Owen C, Abdel-Samad N, Fraser GAM, Lam S, Crump M, Sperlich C, van der Jagt R, Prica A, Couban S, Woyach JA, Ruppert AS, Booth AM, Mandrekar SJ, McDonald G, Shepherd LE, Yen H, Chen BE, Hay AE
Clin Lymphoma Myeloma Leuk
July 1, 2021Mechanisms of resistance to BTK inhibitors in patients with chronic lymphocytic leukemia.
Woyach JA
Clin Adv Hematol Oncol
June 1, 2021Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia.
Heerema NA, Muthusamy N, Zhao Q, Ruppert AS, Breidenbach H, Andritsos LA, Grever MR, Maddocks KJ, Woyach J, Awan F, Long M, Gordon A, Coombes C, Byrd JC
Haematologica
April 5, 2021Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients.
Miller CR, Huang Y, Ruppert AS, Labanowska J, Jaglowski SM, Maddocks KJ, Rogers KA, Bhat S, Kittai AS, Grever M, Lapalombella R, Abruzzo LV, Heerema NA, Byrd JC, Hertlein EK, Woyach JA
Leukemia
March 30, 2021Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia.
Byrd JC, Woyach JA, Furman RR, Martin P, O'Brien S, Brown JR, Stephens DM, Barrientos J, Devereux S, Hillmen P, Pagel JM, Hamdy A, Izumi R, Patel P, Wang MH, Jain N, Wierda WG
Blood
March 6, 2021Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M
Lancet
February 24, 2021Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL.
Chen TL, Harrington B, Truxall J, Wasmuth R, Prouty A, Sloan S, Lehman AM, Sampath D, Orlemans E, Baiocchi RA, Alinari L, Byrd JC, Woyach JA, Hertlein E
J Hematol Oncol
January 15, 2021Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia.
Walker JS, Hing ZA, Harrington B, Baumhardt J, Ozer HG, Lehman A, Giacopelli B, Beaver L, Williams K, Skinner JN, Cempre CB, Sun Q, Shacham S, Stromberg BR, Summers MK, Abruzzo LV, Rassenti L, Kipps TJ, Parikh S, Kay NE, Rogers KA, Woyach JA, Coppola V, Chook YM, Oakes C, Byrd JC, Lapalombella R
J Hematol Oncol
December 1, 2020Characterization and mitigation of fragmentation enzyme-induced dual stranded artifacts.
Gregory T, Ngankeu A, Orwick S, Kautto EA, Woyach JA, Byrd JC, Blachly JS
NAR Genom Bioinform
December 1, 2020Second cancer incidence in CLL patients receiving BTK inhibitors.
Bond DA, Huang Y, Fisher JL, Ruppert AS, Owen DH, Bertino EM, Rogers KA, Bhat SA, Grever MR, Jaglowski SM, Maddocks KJ, Byrd JC, Woyach JA
Leukemia
November 19, 2020Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia.
Khountham S, Shindiapina P, Mo X, Lachowiez C, Wiczer T, Mousa L, Rogers KA, Andritsos LA, Woyach JA, Byrd JC, Spurgeon SE, Awan FT
Leuk Lymphoma
October 13, 2020Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome.
Kittai AS, Bond DA, William B, Saad A, Penza S, Efebera Y, Larkin K, Wall SA, Choe HK, Bhatnagar B, Vasu S, Brammer J, Shindiapina P, Long M, Mims A, O'Donnell L, Bhat SA, Rogers KA, Woyach JA, Byrd JC, Jaglowski SM
Blood Adv
October 13, 2020Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists.
Koenig KL, Huang Y, Dotson EK, Sheredy S, Bhat SA, Byrd JC, Desmond E, Ford J, Iarocci S, Jones JA, Lucas MS, Moran ME, Wiczer TE, Woyach JA, Awan FT, Rogers KA
Blood Adv
September 22, 2020Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma.
Jain N, Singh S, Laliotis G, Hart A, Muhowski E, Kupcova K, Chrbolkova T, Khashab T, Chowdhury SM, Sircar A, Shirazi F, Singh RK, Alinari L, Zhu J, Havranek O, Tsichlis P, Woyach J, Baiocchi R, Samaniego F, Sehgal L
Blood Adv
September 21, 2020Early intervention with lenalidomide in patients with high-risk chronic lymphocytic leukemia.
Thangavadivel S, Zhao Q, Epperla N, Rike LA, Mo X, Badawi M, Bystry D, Phelps MA, Andritsos L, Rogers KA, Jones J, Woyach JA, Byrd JC, Awan FT
Clin Cancer Res
August 14, 2020Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.
Rogers KA, Huang Y, Ruppert AS, Abruzzo LV, Andersen BL, Awan FT, Bhat SA, Dean A, Lucas M, Banks C, Grantier C, Heerema NA, Lozanski G, Maddocks KJ, Valentine TR, Weiss DM, Jones JA, Woyach JA, Byrd JC
J Clin Oncol
June 18, 2020LC-FACSeq is a method for detecting rare clones in leukemia.
Hu EY, Blachly JS, Saygin C, Ozer HG, Workman SE, Lozanski A, Doong TJ, Chiang CL, Bhat S, Rogers KA, Woyach JA, Coombes KR, Jones D, Muthusamy N, Lozanski G, Byrd JC
JCI Insight
April 18, 2020Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Salles G, Wierda WG, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC
Lancet
March 24, 2020Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
Lucas F, Larkin K, Gregory CT, Orwick S, Doong TJ, Lozanski A, Lozanski G, Misra S, Ngankeu A, Ozer HG, Sampath D, Thangavadivel S, Yilmaz AS, Rogers KA, Byrd J, Woyach JA, Blachly JS
Blood
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Woyach has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.
- Eli Lilly and Company
- Genentech
- BeiGene, Ltd.
- AbbVie
- Clinical Education Alliance
- Medscape, Inc.
- Merck Sharp & Dohme
- Syneos
Patient Comments
Dr Woyach is wonderful. She's amazingly talented and intelligent but is able to communicate at a level that's easy to understand.
I loved and appreciated my doctor so much. She cared and you knew it.
My appointment was two hours and 45 minutes long. Every question was answered and everyone took their time. I am very pleased.
Very thorough and answered my questions really well
Perfection
Great team of care providers!
Dr. Woyach is the best! Please don't ever lose her. She is an amazing asset to this hospital. Love her so much!
Excellent discussion. Very thorough and comprehensive. Far exceeded my expectations.
All good
Dr. Woyach is an awesome Dr. I feel like she has my best interests at hand.
Always 100%
Time spent reviewing my condition and questions was excellent. Caring attitude and knowledgable responses was exemplary for a medical care team today.
I could write an article on why Dr. Woyach is the "go to" person for CLL. I have made it quite clear to Dr Woyach and my family that when my current trial drug no longer is effective I wish to be treated at the James by Dr. Woyach and I will move to Columbus on a temporary basis if necessary
Always a good experience seeing Mollie nad Dr. Woyach.
Trust Dr Woyach keeping me alive.
Dr. Woyach took a great interest in my gut symptoms and spent extra time listening to the history, asking pertinent questions.
Dr. Woyach is a PHSICIAN, not a "Provider."She should be referred to as such. She's earned the title and deserves the respect. I would pass this along to your rating agency.
Good Experience
I love my care providers (Molly and Dr Woyach! I recommend them to others that are seeking a CLL Specialist
This was an outstanding experience
Dr Woyack is just outstanding caring person
Never feel rushed, my questions are always answered thoroughly. Rather than telling me not to worry about something they explain the results well and explain why not to worry and what I need to look for that they would have concern about. Wonderful team!
Dr Woyach is knowledgeable, professional and very friendly.
Staff Friendly and Informative. Dr. Woyach answered all my questions.
Dr Woyach and Mollie are amazing. I have to give an extra shout out to Mollie. She took a concern I had and did not dismiss it as many other doctors have done. She did further testing, called me back the following day with the results, and we have been able to fix my particular issue. She cared enough to take the extra step, which has meant the world to me. And please don't ever let Dr Woyach leave! She is nothing short of amazing in every way!
I love Dr. Woyach.
Dr Woyach is an amazing doctor. She is caring in her explanation, positive, & extremely knowledgable in treatment of my disease.
I feel blessed to have Dr Woyach
Have seen Dr Woyach for years and believe in her desions
To a person, my heme team is there for me. Dr Woyach. Mollie Arnott, her nurse practitioner. Megan the researcher for one of the clinical trials I'm doing; Cara another NP. Ashley, Jason and so many others. The best.
Friendly faces and very helpful
Couldn't ask for any better.
The best
I'm thrilled to have such a expertise in my cancer in the Midwest and such a lovely town as Columbus, Ohio
Professional, experianced , very knowledgeable.
I have every confidence in Dr. Woyach.
I had to call the oncology depth a couple of times and they always answered quickly and then helped me with my concerns. Absolute professionals.
Dr. Woyach was wonderful & spent lots of time with us explaining treatment options & answering our many questions!
I am always treated in a very friendly manner. I am more of a friend than a patient. It is very professional.
DR Woyach is a great DR. She is kind and considerate about me and my treatment. I'm lucky to have her as my care provider!
The team explained my tests and discussed additional tests before proceeding. They were efficient and generous with their time
I feel fortunate to be a patient of Dr Womack.
Dr. Woyach is a Rock Star in my opinion! I always love seeing her, even though its only 2x a year...
Exceptional physican, but the visit was unexplained, and unexpectedly brief. Maybe 10-15 minutes.
My providers at OSU, especially Dr. Woyach, are outstanding. In my 67 years I've had many visits with many different providers of all levels & without a doubt I feel (know) that Dr. Woyach is perhaps the best I've encountered. Her intelligence & professionalism alone are second-to-none but when you include her kindness, compassion & understanding, she far exceeds any normal provider. I feel blessed to have her as my most important provider. Thank you Dr. Woyach.
She is great!!!
The physcians sasdsistant that I saw first was also excellent
Dr wyoach is the best!
I feel so fortunate to have Dr. Woyach leading my care team.
Simply & Absolutely: The Best.
All my questions were answered plus Dr. Woyach provided me with so much more information on my options.